Normotim

About the offering

Normopharm Inc is the company behind Normotim, a brain health supplement brand built around a proprietary compound called Lithium Ascorbate. The company is headquartered in Dover, United States, and operates across healthcare, ecommerce, and consumer goods categories with both B2C and subscription models. Core Technology: The company's foundation is the Lithium Ascorbate Molecule — a patented reformulation of lithium (traditionally used as lithium carbonate since 1949) combined with vitamin C (ascorbic acid). The company claims this compound delivers the neuroprotective benefits of lithium without the toxicity and side effects associated with lithium carbonate. The molecule is supported by 40+ internal studies and 20+ peer-reviewed published papers, as well as a completed full GLP preclinical safety package. Patents: Normopharm holds 54 patents globally, including 3 US patents covering lithium ascorbate's anti-stress, anxiolytic, anti-depression activity, and its use in treating alcoholism and alcohol intoxication. Preclinical Claims (from observational/preclinical studies cited on the page): - Depression levels reduced by 39% and anxiety by 35% on the HADS scale over 60 days - BDNF (brain-derived neurotrophic factor) increased by 9% - Visual memory improved by 83%, auditory-verbal memory by 98%, muscle memory by 83% - Neuron survival doubled under glutamate-induced stress and prolonged alcohol toxicity conditions Products: Two products currently launched — Normotim and Lithium Ascorbate 1 mg — sold via Amazon, TikTok Shop, and the company's own webstore (normotim.com). Four additional products are in development for 2026 launch: AgeBalance (cognitive aging and burnout), AddictivaReset (addiction and impulse control), NeuroRenew (neuroprotection and cognitive function), and a Mood and Appetite product (emotional eating and metabolic dysregulation). Traction: The company reports 2M+ units sold globally, revenue growing approximately 2x per year, and an affiliate program with 1,336 influencers posting on Instagram, TikTok, Amazon Storefront, and Amazon Live. It also has distribution partnerships with practitioners and clinics. Market: The company targets the US mental and brain health supplement market, which it sizes at approximately $8.46B combined. The global mental well-being supplements market is cited at $11.48B in 2025, growing at an 8.62% CAGR to $17.36B by 2030. Normopharm states it conservatively targets 0.8% of the US market by 2030, representing approximately $130M in revenue. Roadmap: Following this SAFE round, the company plans to launch new products and scale advertising. Post-SAFE, it intends to initiate R&D for human clinical trials. Following a Series A, full-scale clinical studies are planned. The long-term goal is FDA alignment for a Medical Food category designation for microdose lithium. Funding Structure: The current raise is a SAFE (Simple Agreement for Future Equity) targeting $250K–$300K at a $7M valuation cap, with an early-investor discount. As of the page snapshot, $53,650 had been raised from 9 investors on Wefunder. Team: Led by founder Viacheslav Rastashanskiy (scientist, entrepreneur, 10+ scientific papers, patents in 56 countries), co-founder and strategic advisor Ben A. Rozenshteyn (attorney with background in diagnostics and digital health), and CMO Anna Fofanova (10 years in mental healthcare marketing and HealthTech). Disclaimer noted on page: Products are dietary supplements and have not been evaluated by the FDA. Scientific references do not imply clinical proof of product outcomes. Regulatory pathways including medical food designation are speculative and subject to regulatory review.

FAQ